Improving Health, Health Care and Quality of Life
DENVER, March 11, 2020 /PRNewswire/ -- DaVita Hospital Services Group today announced that Dr. David Mahoney has assumed the role of chief medical officer (CMO). Dr. Mahoney succeeds Dr. Jeff Giullian, who now serves as chief medical officer for DaVita Kidney Care.
"Dr. Mahoney is an experienced leader, who is focused on innovating to deliver highly coordinated kidney care in inpatient settings," said Dr. Giullian. "DaVita Hospital Services Group has a proven history of improving patient outcomes, while also reducing costs to hospitals, and I'm confident that Dr. Mahoney will build on this success."
Dr. Mahoney, a trained interventional nephrologist, joined DaVita in 2017 as CMO for DaVita's vascular access care business. Throughout his career, he has served as the medical director of a DaVita Kidney Care chronic dialysis center, a hospital acute dialysis service and his practice's vascular access center. Dr. Mahoney completed his residency and nephrology fellowship at Walter Reed Army Medical Center and served for 10 years as an Army physician.
When asked what his priorities will be in his new leadership role, Dr. Mahoney said, "I'll continue efforts that support the quality and safety programs we have developed with local hospitals to help more patients return home as quickly as possible. An important part of that is the communication of data to ensure a smooth transition to outpatient care."
According to the United States Renal Data System, it is estimated that patients with end stage kidney disease (ESKD) spend, on average, 11 days per year in the hospital and have a 35% re-admittance rate.
DaVita Hospital Services Group is the first nationally Joint Commission-accredited provider of inpatient kidney care and apheresis.
Through partnerships created with 900 U.S. hospitals over the past 12 years, local hospital care teams work with DaVita clinicians to develop solutions that improve patient care and satisfaction, increase staff efficiency to help meet quality and safety standards, and reduce costs. DaVita Hospital Services provides a variety of inpatient therapies for ESKD and acute kidney injury patients including acute hemodialysis, acute peritoneal dialysis, continuous renal replacement therapy and apheresis.
To learn more about DaVita and its leadership, visit DaVita.com/About.
About DaVita Inc.
DaVita (NYSE: DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. The company is one of the largest providers of kidney care services in the U.S. and has been a leader in clinical quality and innovation for more than 20 years. Through DaVita Kidney Care, the company treats patients with chronic kidney failure and end stage kidney disease. DaVita is committed to bold, patient-centric care models, implementing the latest technologies and moving toward integrated care offerings for all. Through these efforts, DaVita has also become the largest provider of home dialysis in the country. As of December 31, 2019, DaVita served 206,900 patients at 2,753 outpatient dialysis centers in the United States. The company also operated 259 outpatient dialysis centers in ten countries worldwide. DaVita has reduced hospitalizations, improved mortality, and worked collaboratively to propel the kidney care industry to adopt an equitable and high-quality standard of care for all patients, everywhere. To learn more, visit DaVita.com/About.
Certain statements in this press release are forward-looking statements that are subject to risks and uncertainties. These forward-looking statements are based on management's current expectations. Various important factors could cause actual results to differ materially, including the risks identified in our U.S. Securities and Exchange Commission filings. DaVita disclaims any obligation to update any forward-looking statement contained in this press release.
Media Contact Information
SOURCE DaVita Inc.